Qulipta, Aquipta(atogepant)
Aquipta, Qulipta (atogepant) is a small molecule pharmaceutical. Atogepant was first approved as Qulipta on 2021-09-28. It is used to treat migraine disorders in the USA. It has been approved in Europe to treat migraine disorders.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
Qulipta
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| qulipta | New Drug Application | 2025-06-10 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| migraine disorders | EFO_0003821 | D008881 | G43 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ATOGEPANT, QULIPTA, ABBVIE | |||
| 2026-09-28 | NCE | ||
| 2026-04-17 | I-909 | ||
HCPCS
No data
Clinical
Clinical Trials
32 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | 1 | 1 | 16 | 2 | 11 | 30 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Headache | D006261 | — | R51 | — | — | — | — | 2 | 2 |
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | — | — | — | — | 1 | 1 |
| Interstitial cystitis | D018856 | EFO_1000869 | N30.1 | — | — | — | — | 1 | 1 |
| Migraine without aura | D020326 | EFO_0005296 | G43.0 | — | — | — | — | 1 | 1 |
| Migraine with aura | D020325 | EFO_0005295 | G43.1 | — | — | — | — | 1 | 1 |
| Secondary headache disorders | D051271 | — | — | — | — | — | — | 1 | 1 |
| Prescription drug overuse | D000067490 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Atogepant |
| INN | atogepant |
| Description | Atogepant, sold under the brand name QULIPTA, is a medication used to prevent migraines. It is a gepant, an orally active calcitonin gene-related peptide receptor (CGRPR) antagonist.
|
| Classification | Small molecule |
| Drug class | calcitonin gene-related peptide receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H]1[C@H](c2c(F)ccc(F)c2F)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F |
Identifiers
| PDB | — |
| CAS-ID | 1374248-81-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3991065 |
| ChEBI ID | — |
| PubChem CID | 72163100 |
| DrugBank | DB16098 |
| UNII ID | 7CRV8RR151 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Qulipta – AbbVie
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 399 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,346 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use